Amgen (AMGN) Liabilities and Shareholders Equity (2009 - 2026)

Amgen has reported Liabilities and Shareholders Equity for 18 years, with the latest figure at $95.6 billion in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 8.81% year-over-year to $95.6 billion in Q2 2026; TTM through Jun 2026 was $368.9 billion, a 2.47% increase from a year earlier, with the FY2025 full-year figure at $90.6 billion, down 1.36% from the prior year.
• Liabilities and Shareholders Equity was $95.6 billion for Q2 2026 at Amgen, up from $92.5 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $97.2 billion in Q4 2023, with the low at $59.2 billion in Q1 2022.
• Average Liabilities and Shareholders Equity over 5 years is $84.8 billion, with a median of $90.4 billion recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity jumped 52.24% in 2023, then retreated 5.47% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $65.1 billion in 2022, then soared by 49.19% to $97.2 billion in 2023, then fell by 5.47% to $91.8 billion in 2024, then retreated by 1.36% to $90.6 billion in 2025, then advanced by 5.58% to $95.6 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $95.6 billion (Q2 2026), $92.5 billion (Q1 2026), and $90.6 billion (Q4 2025), per Business Quant data.